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 Increase the quality of life 
 Increase the life-span 
 Decrease the frequency of 
hospitalization
 Decrease the frequency HF 
progression  
 Decrease the blood pressure
Enalapril maleat  (EM) - ACE inhibitor,   
one of the drugs of the first line therapy for the 
patients with a  chronic heart failure (HF)
The proved 
effects of EM
at HF:
Heart rate variability (HRV)
 Non-invasive tool for 
assessment of the state of 
neurohumoral regulation
 Independent predictor of the 
sudden death and bed 
outcomes
Object of the study
• 47 patients  HF II-III FC on NYHA 
• HF was caused by a combination 
moderate to severe arterial 
hypertension  and angina 
pectoris FC II on Canadian 
classification 
• Mean  age 64,2+6,8 years
• Male -16, female - 31
Stages of the study
Assessing  of  neurohumoral  regulation 
with   HRV   method    acute    farm 
test:   10-20  mg   of   enalapril    maleat 
 assessing  neurohumoral  regulation 
after   180   minutes     1   month  of   
the   treatment    with   enalapril   maleat         
(15 - 25  mg/day)      assessing    of 
neurohumoral   regulation   and   clinical 
effects 
Heart rate variability method
Spectral characteristics
as neurohumoral regulation
indexes:
1. TP (msek2) – common 
neurohumoral regulation
2. VLF (msek2) – mostly 
humoral activity
3. LF (msek2) - mostly 
sympathetic activity
4. HF (msek2) – mostly 
parasympathetic activity
LF
HF
VLF
Stratification of patients
Acute farm test 
with EM
Two groups:
Group 1: 
Increase of TP 
24 patients
Group 2:
Decrease of TP
23 patients
Results of treatment:
blood pressure and heart rate
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Dynamic of heart failure clinic 
appearance in the groups
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HRV changes in 1 month therapy with EM
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 Basic stage  After therapy
Patient T., female, (group 1), 66 y.o.
Basic stage of HRV
Patient T., female, (group 1), 66 y.o. 
HRV after acute farm test with EM
Patient T., female, (group 1), 66 y.o. 
HRV after 1 month of EM therapy
Patient M., female, (group 2), 64 y.o.
Basic stage of HRV
Patient M., female, (group 2), 64 y.o. 
HRV after acute farm test with EM
Patient M., female, (group 2), 64 y.o. 
HRV after 1 month of EM therapy
Conclusion:
The results have shown, that the efficiency of HF 
therapy by the EM is appreciably determined by 
initial reaction TP HRV on a preparation in acute 
pharmacological trial.
In the group of the patients with increase of TP in 
acute farm test with EM the therapy within one 
month results in rising capacity NGR. 
At the patients with decrease of TP in acute farm 
test with EM capacity after 1 month of therapy 
falls with intensifying of sympathetic influences. 
The research shows necessity of the individual 
approach to treatment HF. 
